89bio (NASDAQ:ETNB) traded up 9% on Tuesday . The stock traded as high as $35.00 and last traded at $33.44, 212,591 shares traded hands during mid-day trading. An increase of 75% from the average session volume of 121,799 shares. The stock had previously closed at $30.67.
In other news, major shareholder Longitude Capital Partners Iii bought 575,000 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The stock was purchased at an average price of $27.00 per share, with a total value of $15,525,000.00. Also, Director Orbimed Advisors Llc bought 837,500 shares of the firm’s stock in a transaction that occurred on Monday, November 11th. The shares were purchased at an average cost of $27.00 per share, with a total value of $22,612,500.00.
89bio Company Profile (NASDAQ:ETNB)
89bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate, BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 that is being developed for the treatment of nonalcoholic steatohepatitis.
Featured Article: What is Forex?
Receive News & Ratings for 89bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 89bio and related companies with MarketBeat.com's FREE daily email newsletter.